Medical - Care Facilities
Compare Stocks
4 / 10Stock Comparison
AMS vs ARAY vs NVCR vs GKOS
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Instruments & Supplies
Medical - Devices
AMS vs ARAY vs NVCR vs GKOS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $13M | $35M | $1.92B | $7.85B |
| Revenue (TTM) | $29M | $429M | $674M | $551M |
| Net Income (TTM) | $-2M | $-46M | $-173M | $-189M |
| Gross Margin | 25.0% | 26.8% | 75.2% | 78.1% |
| Operating Margin | -12.3% | -5.1% | -27.2% | -15.6% |
| Forward P/E | 6.1x | — | — | — |
| Total Debt | $23M | $176M | $290M | $140M |
| Cash & Equiv. | $11M | $57M | $103M | $91M |
AMS vs ARAY vs NVCR vs GKOS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| American Shared Hos… (AMS) | 100 | 109.2 | +9.2% |
| Accuray Incorporated (ARAY) | 100 | 14.0 | -86.0% |
| NovoCure Limited (NVCR) | 100 | 25.0 | -75.0% |
| Glaukos Corporation (GKOS) | 100 | 344.2 | +244.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AMS vs ARAY vs NVCR vs GKOS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AMS carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 32.9%, EPS growth 245.9%, 3Y rev CAGR 17.1%
- 32.9% revenue growth vs ARAY's 2.7%
- -7.6% margin vs GKOS's -34.3%
- -3.8% ROA vs GKOS's -20.1%, ROIC -5.8% vs -9.2%
ARAY plays a supporting role in this comparison — it may shine differently against other peers.
NVCR lags the leaders in this set but could rank higher in a more targeted comparison.
GKOS is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- beta 1.20
- 457.1% 10Y total return vs NVCR's 30.3%
- Lower volatility, beta 1.20, Low D/E 21.3%, current ratio 4.69x
- Beta 1.20, current ratio 4.69x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 32.9% revenue growth vs ARAY's 2.7% | |
| Quality / Margins | -7.6% margin vs GKOS's -34.3% | |
| Stability / Safety | Beta 1.20 vs ARAY's 2.42, lower leverage | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +52.0% vs ARAY's -78.4% | |
| Efficiency (ROA) | -3.8% ROA vs GKOS's -20.1%, ROIC -5.8% vs -9.2% |
AMS vs ARAY vs NVCR vs GKOS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
AMS vs ARAY vs NVCR vs GKOS — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
GKOS leads in 2 of 6 categories
ARAY leads 1 • AMS leads 1 • NVCR leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
GKOS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NVCR is the larger business by revenue, generating $674M annually — 22.9x AMS's $29M. AMS is the more profitable business, keeping -7.6% of every revenue dollar as net income compared to GKOS's -34.3%. On growth, GKOS holds the edge at +41.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $29M | $429M | $674M | $551M |
| EBITDAEarnings before interest/tax | $2M | -$15M | -$165M | -$40M |
| Net IncomeAfter-tax profit | -$2M | -$46M | -$173M | -$189M |
| Free Cash FlowCash after capex | -$10M | -$28M | -$48M | -$18M |
| Gross MarginGross profit ÷ Revenue | +25.0% | +26.8% | +75.2% | +78.1% |
| Operating MarginEBIT ÷ Revenue | -12.3% | -5.1% | -27.2% | -15.6% |
| Net MarginNet income ÷ Revenue | -7.6% | -10.8% | -25.7% | -34.3% |
| FCF MarginFCF ÷ Revenue | -34.7% | -6.5% | -7.1% | -3.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.5% | -7.4% | +12.3% | +41.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -56.7% | -6.1% | -100.0% | -6.3% |
Valuation Metrics
ARAY leads this category, winning 2 of 4 comparable metrics.
Valuation Metrics
On an enterprise value basis, AMS's 7.5x EV/EBITDA is more attractive than ARAY's 11.0x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $13M | $35M | $1.9B | $7.9B |
| Enterprise ValueMkt cap + debt − cash | $25M | $154M | $2.1B | $7.9B |
| Trailing P/EPrice ÷ TTM EPS | 6.09x | -18.91x | -13.80x | -40.90x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | 0.93x | — | — | — |
| EV / EBITDAEnterprise value multiple | 7.51x | 10.99x | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.46x | 0.08x | 2.92x | 15.47x |
| Price / BookPrice ÷ Book value/share | 0.45x | 0.37x | 5.51x | 11.69x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
Profitability & Efficiency
AMS leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
AMS delivers a -7.9% return on equity — every $100 of shareholder capital generates $-8 in annual profit, vs $-77 for ARAY. GKOS carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to ARAY's 2.17x. On the Piotroski fundamental quality scale (0–9), ARAY scores 6/9 vs GKOS's 3/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -7.9% | -77.5% | -50.8% | -26.5% |
| ROA (TTM)Return on assets | -3.8% | -10.1% | -16.5% | -20.1% |
| ROICReturn on invested capital | -5.8% | +3.0% | -16.4% | -9.2% |
| ROCEReturn on capital employed | -6.4% | +2.8% | -28.9% | -10.3% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 | 5 | 3 |
| Debt / EquityFinancial leverage | 0.77x | 2.17x | 0.85x | 0.21x |
| Net DebtTotal debt minus cash | $12M | $119M | $187M | $49M |
| Cash & Equiv.Liquid assets | $11M | $57M | $103M | $91M |
| Total DebtShort + long-term debt | $23M | $176M | $290M | $140M |
| Interest CoverageEBIT ÷ Interest expense | -1.35x | -1.86x | -96.80x | -18.69x |
Total Returns (Dividends Reinvested)
GKOS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GKOS five years ago would be worth $16,155 today (with dividends reinvested), compared to $606 for ARAY. Over the past 12 months, GKOS leads with a +52.0% total return vs ARAY's -78.4%. The 3-year compound annual growth rate (CAGR) favors GKOS at 31.7% vs ARAY's -56.6% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -4.3% | -65.5% | +28.3% | +21.2% |
| 1-Year ReturnPast 12 months | -27.4% | -78.4% | +1.1% | +52.0% |
| 3-Year ReturnCumulative with dividends | -28.0% | -91.8% | -75.7% | +128.7% |
| 5-Year ReturnCumulative with dividends | -41.1% | -93.9% | -91.3% | +61.5% |
| 10-Year ReturnCumulative with dividends | -4.7% | -94.5% | +30.3% | +457.1% |
| CAGR (3Y)Annualised 3-year return | -10.4% | -56.6% | -37.6% | +31.7% |
Risk & Volatility
Evenly matched — AMS and GKOS each lead in 1 of 2 comparable metrics.
Risk & Volatility
AMS is the less volatile stock with a -0.02 beta — it tends to amplify market swings less than ARAY's 2.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GKOS currently trades 91.4% from its 52-week high vs ARAY's 14.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.02x | 2.42x | 2.20x | 1.20x |
| 52-Week HighHighest price in past year | $3.11 | $2.10 | $20.06 | $146.75 |
| 52-Week LowLowest price in past year | $1.25 | $0.28 | $9.82 | $73.16 |
| % of 52W HighCurrent price vs 52-week peak | +64.6% | +14.0% | +83.9% | +91.4% |
| RSI (14)Momentum oscillator 0–100 | 63.8 | 58.4 | 69.8 | 63.0 |
| Avg Volume (50D)Average daily shares traded | 138K | 1.4M | 1.5M | 678K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: NVCR as "Buy", GKOS as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs 9.3% for GKOS (target: $147).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Buy | Buy |
| Price TargetConsensus 12-month target | — | — | $33.50 | $146.67 |
| # AnalystsCovering analysts | — | — | 15 | 24 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
GKOS leads in 2 of 6 categories (Income & Cash Flow, Total Returns). ARAY leads in 1 (Valuation Metrics). 1 tied.
AMS vs ARAY vs NVCR vs GKOS: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is AMS or ARAY or NVCR or GKOS a better buy right now?
For growth investors, American Shared Hospital Services (AMS) is the stronger pick with 32.
9% revenue growth year-over-year, versus 2. 7% for Accuray Incorporated (ARAY). American Shared Hospital Services (AMS) offers the better valuation at 6. 1x trailing P/E, making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AMS or ARAY or NVCR or GKOS?
Over the past 5 years, Glaukos Corporation (GKOS) delivered a total return of +61.
5%, compared to -93. 9% for Accuray Incorporated (ARAY). Over 10 years, the gap is even starker: GKOS returned +457. 1% versus ARAY's -94. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AMS or ARAY or NVCR or GKOS?
By beta (market sensitivity over 5 years), American Shared Hospital Services (AMS) is the lower-risk stock at -0.
02β versus Accuray Incorporated's 2. 42β — meaning ARAY is approximately -15516% more volatile than AMS relative to the S&P 500. On balance sheet safety, Glaukos Corporation (GKOS) carries a lower debt/equity ratio of 21% versus 2% for Accuray Incorporated — giving it more financial flexibility in a downturn.
04Which is growing faster — AMS or ARAY or NVCR or GKOS?
By revenue growth (latest reported year), American Shared Hospital Services (AMS) is pulling ahead at 32.
9% versus 2. 7% for Accuray Incorporated (ARAY). On earnings-per-share growth, the picture is similar: American Shared Hospital Services grew EPS 245. 9% year-over-year, compared to -18. 4% for Glaukos Corporation. Over a 3-year CAGR, GKOS leads at 21. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AMS or ARAY or NVCR or GKOS?
American Shared Hospital Services (AMS) is the more profitable company, earning 7.
7% net margin versus -37. 0% for Glaukos Corporation — meaning it keeps 7. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARAY leads at 1. 7% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — GKOS leads at 77. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — AMS or ARAY or NVCR or GKOS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is AMS or ARAY or NVCR or GKOS better for a retirement portfolio?
For long-horizon retirement investors, American Shared Hospital Services (AMS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
02)). Accuray Incorporated (ARAY) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMS: -4. 7%, ARAY: -94. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between AMS and ARAY and NVCR and GKOS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AMS is a small-cap high-growth stock; ARAY is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; GKOS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.